Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity ...Middle East

Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity )

Also on site :

• Numbrix 9 - June 27
• Who Was Eliminated on 'RuPaul's Drag Race All Stars' Season 10 Episode 9 This Week?
• Security forces disperse Togo protesters demanding president’s resignation